Guangrong Zheng

发表

Computational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2.

Fang Zheng, Chang-Guo Zhan, L. Dwoskin, 2007, Bioorganic & medicinal chemistry.

GZ‐793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter‐2

L. Dwoskin, P. Crooks, Guangrong Zheng, 2017, European journal of pharmacology.

Discovery of piperlongumine as a potential novel lead for the development of senolytic agents

Daohong Zhou, Yingying Wang, Jianhui Chang, 2016, Aging.

GZ‐793A, a lobelane analog, interacts with the vesicular monoamine transporter‐2 to inhibit the effect of methamphetamine

L. Dwoskin, P. Crooks, Guangrong Zheng, 2013, Journal of neurochemistry.

Vesicular monoamine transporter 2: Role as a novel target for drug development

L. Dwoskin, P. Crooks, Guangrong Zheng, 2006, The AAPS Journal.

Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats

L. Dwoskin, P. Crooks, D. J. Stairs, 2018, Behavioural pharmacology.

Lobelane Inhibits Methamphetamine-Evoked Dopamine Release via Inhibition of the Vesicular Monoamine Transporter-2

L. Dwoskin, P. Crooks, S. Norrholm, 2010, Journal of Pharmacology and Experimental Therapeutics.

A mild and efficient AgSbF6-catalyzed synthesis of fully substituted pyrroles through a sequential propargylation/amination/cycloisomerization reaction.

H. Hendrickson, Guangrong Zheng, Xingui Liu, 2014, Tetrahedron.

Overcoming Cancer Drug Resistance Utilizing PROTAC Technology

Guangrong Zheng, M. Burke, Alexis Smith, 2022, Frontiers in Cell and Developmental Biology.

PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors

Daohong Zhou, Guangrong Zheng, Sajid Khan, 2020, Exploration of targeted anti-tumor therapy.

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

J. Elisseeff, J. Campisi, M. Almeida, 2020, Nature Communications.

Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity.

Daohong Zhou, Yaxia Yuan, Guangrong Zheng, 2020, European journal of medicinal chemistry.

Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL.

Daohong Zhou, Guangrong Zheng, Dinesh Thummuri, 2019, Chemical communications.

Cellular senescence and radiation-induced pulmonary fibrosis.

P. Okunieff, D. Citrin, Daohong Zhou, 2019, Translational research : the journal of laboratory and clinical medicine.

Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity

J. Campisi, Daohong Zhou, Guangrong Zheng, 2020, Aging cell.

(2S,6S)-1-Methyl-2,6-trans-distyrylpiperidinium chloride

L. Dwoskin, P. Crooks, S. Parkin, 2009, Acta crystallographica. Section E, Structure reports online.

Computational neural network analysis of the affinity of N-n-alkylnicotinium salts for the alpha4beta2* nicotinic acetylcholine receptor.

L. Dwoskin, P. Crooks, C. Zhan, 2009, Journal of enzyme inhibition and medicinal chemistry.

Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation.

Daohong Zhou, Yingying Wang, H. Hendrickson, 2018, Bioorganic & medicinal chemistry.

Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216

A. Loguinov, C. Vulpe, R. Hromas, 2021, Molecular Cancer Therapeutics.

Molecular Dynamics Guided Design of Tocoflexol: A New Radioprotectant Tocotrienol with Enhanced Bioavailability

S. Thakkar, M. Boerma, M. Hauer-Jensen, 2014, Drug development research.

Lobelane analogues as novel ligands for the vesicular monoamine transporter-2.

L. Dwoskin, P. Crooks, Guangrong Zheng, 2005, Bioorganic & medicinal chemistry.

Synthesis and evaluation of a series of tropane analogues as novel vesicular monoamine transporter-2 ligands.

L. Dwoskin, P. Crooks, Guangrong Zheng, 2005, Bioorganic & medicinal chemistry letters.

Novel bis-, tris-, and tetrakis-tertiary amino analogs as antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release.

L. Dwoskin, P. Crooks, Zhenfa Zhang, 2011, Bioorganic & medicinal chemistry letters.

Syntheses of two diastereoisomers of panaxytriol, a potent antitumor agent isolated from panax ginseng

W. Lu, Guangrong Zheng, Junchao Cai, 1999 .

Synthesis and Liver Microsomal Metabolic Stability Studies of a Fluorine‐Substituted δ‐Tocotrienol Derivative

Daohong Zhou, H. Hendrickson, Yaxia Yuan, 2020, ChemMedChem.

1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2.

L. Dwoskin, P. Crooks, Guangrong Zheng, 2016, Bioorganic & medicinal chemistry letters.

Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse.

L. Dwoskin, P. Crooks, Guangrong Zheng, 2013, MedChemComm.

Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy

Stephen L. Brown, C. N. Coleman, C. Coleman, 2021, Journal of the National Cancer Institute.

Synthesis of O- and N-alkylated products of 1,2,3,4-tetrahydrobenzo[c][2,7]naphthyrin-5(6H)-one.

L. Dwoskin, Guangrong Zheng, S. Bommagani, 2015, Tetrahedron letters.

of activity selectively eliminates senescent cells in part via restoration of p53 activity.

J. Campisi, Daohong Zhou, Guangrong Zheng, 2020 .

The curcumin analog EF24 is a novel senolytic agent

Daohong Zhou, Guangrong Zheng, Rongping Zhang, 2019, Aging.

An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic α6β2* antagonist r-bPiDI.

L. Dwoskin, P. Crooks, M. Bardo, 2018, Drug and alcohol dependence.

Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins

Guangrong Zheng, S. Poddar, Peiyi Zhang, 2022, Expert opinion on therapeutic patents.

Absolute configuration of falcarinol, a potent antitumor agent commonly occurring in plants

W. Lu, H. Aisa, Guangrong Zheng, 1999 .

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

F. Kaye, S. Kopetz, C. Allegra, 2022, Journal of Hematology & Oncology.

Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice

F. Kaye, R. Hromas, Nan Hua, 2022, bioRxiv.

Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs.

Lisa Y. Zhao, Daiqing Liao, Guangrong Zheng, 2020, Chemical communications.

Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.

Ashish P. Vartak, L. Dwoskin, P. Crooks, 2011, Current topics in medicinal chemistry.

Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2.

L. Dwoskin, P. Crooks, Guangrong Zheng, 2016, Bioorganic & medicinal chemistry letters.

Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter.

L. Dwoskin, P. Crooks, S. Norrholm, 2005, Journal of medicinal chemistry.

A Facile Semisynthesis and Evaluation of Garcinoic Acid and Its Analogs for the Inhibition of Human DNA Polymerase β

M. Zafar, R. Eoff, Guangrong Zheng, 2020, Molecules.

Synthesis of (2R,8' S,3' E)-δ-tocodienol, a tocoflexol family member designed to have a superior pharmacokinetic profile compared to δ-tocotrienol.

P. Crooks, M. Boerma, Daohong Zhou, 2016, Tetrahedron.

Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis

R. Hromas, A. Jaiswal, E. Williamson, 2022, Cancer Chemotherapy and Pharmacology.

Targeting BCL-XL in fibrolamellar hepatocellular carcinoma

S. Simon, P. Coffino, M. Yarchoan, 2022, JCI insight.

New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.

Hui Zhang, Chunxiao Zhang, Fei Lu, 2018, Bioorganic & medicinal chemistry.

Licochalcone A is a natural selective inhibitor of arginine methyltransferase 6

Donghang Cheng, Yan-wen Yang, Guangrong Zheng, 2020, The Biochemical journal.

The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats

L. Dwoskin, P. Crooks, M. Bardo, 2012, Psychopharmacology.

The characterization of a novel rigid nicotine analog with alpha7-selective nAChR agonist activity and modulation of agonist properties by boron inclusion.

R. Papke, L. Dwoskin, P. Crooks, 2005, Bioorganic & medicinal chemistry letters.

PROTAC therapy as a new targeted therapy for lung cancer

F. Kaye, Guangrong Zheng, Lizi Wu, 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

Absolute Configuration of Falcarinol, a Potent Antitumor Agent Commonly Occurring in Plants.

Wei Lu, H. Aisa, Guangrong Zheng, 1999 .

Syntheses of Two Diastereoisomers of Panaxytriol, a Potent Antitumor Agent Isolated from Panax ginseng.

Wei Lu, Guangrong Zheng, Junchao Cai, 1999 .

r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement

Joshua S. Beckmann, L. Dwoskin, P. Crooks, 2015, Neurochemical Research.

A mild and efficient AgSbF6-catalyzed synthesis of fully substituted pyrroles through a sequential propargylation/amination/cycloisomerization reaction.

H. Hendrickson, Guangrong Zheng, Xingui Liu, 2014, Tetrahedron.

Amberlite IR-120H as an efficient and versatile solid phase catalyst for nucleophilic substitution of propargylic alcohols

H. Hendrickson, Guangrong Zheng, S. Gujarathi, 2013 .

AgSbF6-catalyzed efficient propargylation/cycloisomerization tandem reaction for the synthesis of fully substituted furans and new insights into the reaction mechanism

Guangrong Zheng, S. Gujarathi, 2015 .

Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists.

L. Dwoskin, C. Zhan, Xiaoqin Huang, 2013, Journal of medicinal chemistry.

The Preparation of 2‐Arylmethylidene‐8‐methyl‐8‐azabicyclo[3.2.1]octan‐3‐ones

L. Dwoskin, P. Crooks, Guangrong Zheng, 2004 .

Synthesis of Lobeline, Lobelane and their Analogues. A Review

P. Crooks, Guangrong Zheng, 2015, Organic preparations and procedures international.

Stereocontrolled synthesis and pharmacological evaluation of cis-2,6-diphenethyl-1-azabicyclo[2.2.2]octanes as lobelane analogues.

L. Dwoskin, P. Crooks, Guangrong Zheng, 2009, The Journal of organic chemistry.

First total synthesis of optically active panaxydol, a potential antitumor agent isolated from Panax ginseng

Haji, Guangrong Zheng, Junchao Cai, 1998 .

Novel Linear Lipopeptide Paenipeptins with Potential for Eradicating Biofilms and Sensitizing Gram-Negative Bacteria to Rifampicin and Clarithromycin.

M. Smeltzer, Guangrong Zheng, En Huang, 2017, Journal of medicinal chemistry.

Astins K—P, Six New Chlorinated Cyclopentapeptides from Aster tataricus.

N. Tan, Guangrong Zheng, Wen-jun He, 2014 .

Tetrakis-azaaromatic quaternary ammonium salts: novel subtype-selective antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release.

L. Dwoskin, P. Crooks, Zhenfa Zhang, 2008, Bioorganic & medicinal chemistry letters.

Discovery of non-peptide, small molecule antagonists of α9α10 nicotinic acetylcholine receptors as novel analgesics for the treatment of neuropathic and tonic inflammatory pain.

L. Dwoskin, P. Crooks, Zhenfa Zhang, 2011, Bioorganic & medicinal chemistry letters.

Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition.

Daohong Zhou, Nan Hua, Yaxia Yuan, 2021, Journal of medicinal chemistry.

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics

Daohong Zhou, Yaxia Yuan, Guangrong Zheng, 2020, Oncogene.

Lobeline Analogs with Enhanced Affinity and Selectivity for Plasmalemma and Vesicular Monoamine Transporters

L. Dwoskin, P. Crooks, S. Norrholm, 2004, Journal of Pharmacology and Experimental Therapeutics.

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

R. Hromas, Daohong Zhou, Yaxia Yuan, 2020, Journal of Hematology & Oncology.

Assays and technologies for developing proteolysis targeting chimera degraders

Daohong Zhou, Yaxia Yuan, Guangrong Zheng, 2020, Future medicinal chemistry.

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

A. Ferrando, M. Konopleva, P. Houghton, 2019, Nature Medicine.

Oxidation resistance 1 is a novel senolytic target

A. Tackett, J. Campisi, Daohong Zhou, 2018, Aging cell.

SYNTHESES OF TWO ENANTIOMERS OF EICOS-(4E)-EN-1-YN-3-OL, A BIOACTIVE COMPONENT OF THE MARINE SPONGE CRIBROCHALINA VASCULUM

Guangrong Zheng, Junchao Cai, W. Lu, 1999 .

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

R. Koch, D. Weinstock, Daohong Zhou, 2020, Journal of Hematology & Oncology.

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

J. Elisseeff, J. Campisi, M. Almeida, 2020, Nature Communications.

Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines.

Daohong Zhou, J. Pei, Yaxia Yuan, 2020, European journal of medicinal chemistry.

Targeting anti-apoptotic BCL-2 family proteins for cancer treatment.

Daohong Zhou, Guangrong Zheng, Xingui Liu, 2020, Future medicinal chemistry.

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

A. Ferrando, M. Konopleva, P. Houghton, 2019, Nature Medicine.

Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells

S. Zheng, Daohong Zhou, yang-xin fu, 2021, Nature Communications.

Extending the Analysis of Nicotinic Receptor Antagonists with the Study of A6 Nicotinic Receptor Subunit Chimeras

R. Papke, L. Dwoskin, P. Crooks, 2022 .

Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.

L. Dwoskin, P. Crooks, M. Bardo, 2010, Biochemical pharmacology.

Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD).

R. Papke, L. Dwoskin, P. Crooks, 2007, Biochemical pharmacology.

Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats

L. Dwoskin, P. Crooks, M. Bardo, 2013, Pharmacology Biochemistry and Behavior.

Mitigation of late cardiovascular effects of oxygen ion radiation by γ-tocotrienol in a mouse model.

M. Boerma, Preeti Singh, R. Landes, 2021, Life sciences in space research.

Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats

L. Dwoskin, P. Crooks, M. Bardo, 2018, Psychopharmacology.

Piperlongumine (PL) conjugates induce targeted protein degradation

J. Licht, Nan Hua, J. Pei, 2023, bioRxiv.

First total synthesis of panaxytriol, a potent antitumor agent isolated from Panax ginseng

Wei Lu, Guangrong Zheng, Junchao Cai, 1998 .

ROS-mediated SRMS activation confers platinum resistance in ovarian cancer

Yizhu Lin, Tao Li, Qianqian Song, 2023, Oncogene.

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

M. Konopleva, R. Hromas, S. Weintraub, 2021, Nature Communications.

Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence.

L. Dwoskin, P. Crooks, M. Bardo, 2009, Nebraska Symposium on Motivation. Nebraska Symposium on Motivation.

NCAPG Promotes Tumor Progression and Modulates Immune Cell Infiltration in Glioma

T. Han, Hengyu Li, Guangrong Zheng, 2022, Frontiers in Oncology.

The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats

L. Dwoskin, P. Crooks, M. Bardo, 2012, Psychopharmacology.

GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine

L. Dwoskin, P. Crooks, M. Bardo, 2019, The Journal of Pharmacology and Experimental Therapeutics.

New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders

L. Dwoskin, P. Crooks, M. Bardo, 2018, The AAPS Journal.

Effects of VMAT2 inhibitors lobeline and GZ‐793A on methamphetamine‐induced changes in dopamine release, metabolism and synthesis in vivo

L. Dwoskin, P. Crooks, M. Bardo, 2013, Journal of neurochemistry.

Novel N-1,2-Dihydroxypropyl Analogs of Lobelane Inhibit Vesicular Monoamine Transporter-2 Function and Methamphetamine-Evoked Dopamine Release

L. Dwoskin, P. Crooks, Guangrong Zheng, 2011, Journal of Pharmacology and Experimental Therapeutics.

Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters.

L. Dwoskin, P. Crooks, Guangrong Zheng, 2006, Bioorganic & medicinal chemistry letters.

Synthesis and in vitro evaluation of water-soluble 1,4-diphenethylpiperazine analogs as novel inhibitors of the vesicular monoamine transporter-2.

L. Dwoskin, P. Crooks, Guangrong Zheng, 2016, Bioorganic & medicinal chemistry letters.

The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats

Joshua S. Beckmann, L. Dwoskin, P. Crooks, 2012, Psychopharmacology.

Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.

S. Mustjoki, M. Konopleva, M. Andreeff, 2023, Haematologica.

DyScore: A Boosting Scoring Method with Dynamic Properties for Identifying True Binders and Non-binders in Structure-based Drug Discovery

Daohong Zhou, Xiaoling Li, Yaxia Yuan, 2021, bioRxiv.

Senolytic Drug Development

Daohong Zhou, Guangrong Zheng, Yonghan He, 2020 .

Microscopic binding of M5 muscarinic acetylcholine receptor with antagonists by homology modeling, molecular docking, and molecular dynamics simulation.

Chang-Guo Zhan, C. Zhan, Xiaoqin Huang, 2012, The journal of physical chemistry. B.

Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader

D. Sampath, N. Jain, W. Wierda, 2022, Blood.

Bis-azaaromatic quaternary ammonium salts as ligands for the blood-brain barrier choline transporter.

W. Geldenhuys, L. Dwoskin, P. Crooks, 2010, Bioorganic & medicinal chemistry letters.

Bis-azaaromatic quaternary ammonium salts as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release: An investigation of binding conformation.

L. Dwoskin, P. Crooks, Zhenfa Zhang, 2007, Bioorganic & medicinal chemistry letters.

Asymmetric synthesis of (S)- and (R)-norketamine via Sharpless asymmetric dihydroxylation/Ritter amination sequence

P. Crooks, Guangrong Zheng, M. Hojahmat, 2015 .

Deuteration of the farnesyl terminal methyl groups of δ-tocotrienol and its effects on the metabolic stability and ability of inducing G-CSF production.

P. Crooks, Daohong Zhou, H. Hendrickson, 2020, Bioorganic & medicinal chemistry.

Muscarinic agonist, (±)-quinuclidin-3-yl-(4-fluorophenethyl)(phenyl)carbamate: High affinity, but low subtype selectivity for human M1 - M5 muscarinic acetylcholine receptors.

L. Dwoskin, Guangrong Zheng, K. Siripurapu, 2019, Bioorganic & medicinal chemistry letters.

Computational neural network analysis of the affinity of N-n-alkylnicotinium salts for the α4β2* nicotinic acetylcholine receptor

Fang Zheng, Peter A. Crooks, Chang-Guo Zhan, 2009 .

Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2.

L. Dwoskin, P. Crooks, Guangrong Zheng, 2008, Bioorganic & medicinal chemistry letters.

YAP at the Crossroads of Biomechanics and Drug Resistance in Human Cancer

Michael C. Chung, C. Vulpe, J. Guan, 2023, International journal of molecular sciences.

HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation.

Daiqing Liao, Guangrong Zheng, Weizhou Zhang, 2023, Cell chemical biology.

Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216

A. Loguinov, C. Vulpe, R. Hromas, 2021, Molecular Cancer Therapeutics.

Selective Inhibition of Acetylcholine-evoked Responses of ␣7 Neuronal Nicotinic Acetylcholine Receptors by Novel Tris-and Tetrakis-azaaromatic Quaternary Ammonium Antagonists Differential Inhibition of Ach-evoked Responses of Neuronal Nicotinic Receptors in Rat Brain Slices by Selective Nachr Antago

R. Papke, L. Dwoskin, P. Crooks, 2009 .

Extending the analysis of nicotinic receptor antagonists with the study of α6 nicotinic receptor subunit chimeras

R. Papke, L. Dwoskin, P. Crooks, 2008, Neuropharmacology.

The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats

Joshua S. Beckmann, L. Dwoskin, P. Crooks, 2011, Psychopharmacology.

Selective Inhibition of Acetylcholine-Evoked Responses of α7 Neuronal Nicotinic Acetylcholine Receptors by Novel tris- and tetrakis-Azaaromatic Quaternary Ammonium Antagonists

R. Papke, L. Dwoskin, P. Crooks, 2009, Molecular Pharmacology.

Novel bis-, tris-, and tetrakis-tertiary amino analogs as antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release.

L. Dwoskin, Zhenfa Zhang, Guangrong Zheng, 2011, Bioorganic & medicinal chemistry letters.

Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats

L. Dwoskin, P. Crooks, M. Bardo, 2018, Psychopharmacology.

Piperlongumine conjugates induce targeted protein degradation.

J. Licht, Nan Hua, J. Pei, 2023, Cell Chemical Biology.

Discovery of piperlongumine as a potential novel lead for the development of senolytic agents

Daohong Zhou, Yingying Wang, Jianhui Chang, 2016, Aging.

Phenyl Ring-Substituted Lobelane Analogs: Inhibition of [3H]Dopamine Uptake at the Vesicular Monoamine Transporter-2

L. Dwoskin, P. Crooks, Guangrong Zheng, 2011, Journal of Pharmacology and Experimental Therapeutics.

Unleashing the Power of NR4A1 Degradation as a Novel Strategy for Cancer Immunotherapy

K. Smalley, Guangrong Zheng, Yuewan Luo, 2023, bioRxiv.